CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
免疫佐剂分子（LAG-3、TIM-3、OX-40）在乳腺癌新辅助化疗中表达的临床意义
英文原题：Clinical Significance of Expression of Immunoadjuvant Molecules (LAG-3, TIM-3, OX-40) in Neoadjuvant Chemotherapy for Breast Cancer.
查看英文原题
Clinical Significance of Expression of Immunoadjuvant Molecules (LAG-3, TIM-3, OX-40) in Neoadjuvant Chemotherapy for Breast Cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
我们的研究结果表明，LAG-3 可能成为 TNBC 和 HER2BC 等高度恶性乳腺癌中的一种生物标志物，能够预测 NAC 的治疗疗效。
研究思路结论见上方概要
癌细胞和癌症微环境中存在多种抑制对癌症免疫反应的免疫抑制因子。共抑制和共刺激受体作为免疫佐剂分子在T细胞上动态表达，调节T细胞的活性状态。在本报告中，我们聚焦于LAG-3、TIM-3和OX-40等免疫佐剂分子，这些分子的已发表报道较少。我们研究了LAG-3、TIM-3和OX-40在TIL（肿瘤浸润淋巴细胞）（TILs）中的表达，并从临床角度验证了其表达与新辅助热疗（NAC）相关的意义。
共177例可切除早期乳腺癌患者接受了NAC治疗。通过免疫组化评估雌激素受体（ER）、孕激素受体（PgR）、人表皮生长因子受体2（HER2）、Ki67、LAG-3、TIM-3和OX-40状态。
低-LAG-3表达组在三阴性乳腺癌（TNBC）（p=0.038）和HER2富集型乳腺癌（HER2BC）（p=0.021）中显著小于高表达组，而病理完全缓解（pCR）患者总数更多（p<0.001）。在TNBC和HER2BC中，低-LAG-3表达组的pCR率显著高于高-LAG-3表达组（分别为p<0.001和p=0.02）。此外，多因素分析显示，低-LAG-3表达状态是良好预后的独立预测因素（TNBC：p=0.014，HR=8.124；HER2BC：p=0.048，HR=10.400）。
展开英文摘要原文
A total of 177 patients with resectable early-stage breast cancer were treated with NAC. Estrogen receptor (ER), progesterone receptor (PgR), human epidermal growth factor receptor 2 (HER2), Ki67, LAG-3, TIM-3 and OX-40 status were assessed by immunohistochemistry.
The group with low-LAG-3 expression was significantly smaller than the group with high expression in triple-negative breast cancer (TNBC) (p=0.038) and HER2-enriched breast cancer (HER2BC) (p=0.021), while the total number of pathological complete response (pCR) patients was greater (p<0.001). In TNBC and HER2BC, the pCR rate was significantly higher in the low-LAG-3 expression group than in the high-LAG-3 expression group (p<0.001 and p=0.02, respectively). Moreover, on multivariate analysis low-LAG-3 expression status was an independent predictor of favorable prognosis (TNBC: p=0.014, HR=8.124; HER2BC: p=0.048, HR=10.400).
Our findings suggest that LAG-3 may become a biomarker in highly malignant breast cancers such as TNBC and HER2BC that can predict the therapeutic efficacy of NAC.
论文信息
- 作者
- Asano Y、Kashiwagi S、Takada K、Ishihara S、Goto W、Morisaki T、Shibutani M、Tanaka H
- 第一作者单位
- Department of Breast and Endocrine Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan.Japan
- 通讯作者单位
- Department of Breast and Endocrine Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan spqv9ke9@view.ocn.ne.jp.Japan
- 期刊
- Anticancer research2022 Jan
- 原文标识
- PubMed 34969718 · DOI 10.21873/anticanres.15466